Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
Cancer Research and Treatment. 2020;52(3):730-738 
A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride
International Journal of Clinical Practice. 2013;67(4):351-355
SP-036: Immunity and immune toxicity: clinical management of immune checkpoint inhibition
Radiotherapy and Oncology. 2017;122:21
Immune Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
Clinical Therapeutics. 2015;37(4):753-754
Immune checkpoint inhibitors: a perspective of established and potential combination therapy
Annals of Oncology. 2019;30:vi33
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Cell. 2015;161(2):205-214
Immune Checkpoint Blockade in Melanoma Patients Induces Thyroid Autoimmune Disease
Clinical Thyroidology. 2016;28(10):299-302
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk
International Journal of Clinical Practice. 2008;62(5):781-790
The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy
Pigment Cell & Melanoma Research. 2011;24(6):1116-1132
SP-0423: The implications & challenges for clinical trial design involving radiotherapy
Radiotherapy and Oncology. 2013;106:S163